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Abstract. Chronic myeloid leukemia (CML) is character-
ized by the translocation t(9;22)(q34;q11) [Philadelphia (Ph) 
chromosome). Although not frequently occurring, additional 
chromosome abnormalities (ACAs) can be detected at diag-
nosis and a number have been associated with an adverse 
cytogenetic and molecular outcome. The present study reports a 
case of CML presenting with the translocation t(1;11)(q21;q23) 
and a cryptic Ph chromosome. The presence of ACAs could 
generate greater genetic instability, promoting the emergence 
of further alterations. The present findings suggest that t(1;11)
(q21;q23) can prevent a good response to tyrosine kinase 
inhibitor (TKI) therapy developing a primary resistance. In 
the present patient, at a recent follow-up, the T315I mutation 
was detected. This mutation confers full resistance to all avail-
able TKI, except ponatinib, which was not a therapeutic option 
due to comorbidities.
Introduction
Chronic myeloid leukemia (CML) is a clonal disease of 
pluripotent hematopoietic stem cells that is characterized 
by the Philadelphia (Ph) chromosome with the reciprocal 
translocation t(9;22)(q34;q11). At diagnosis, the majority of 
cases (85%) exhibit the typical Ph chromosome as the only 
cytogenetic finding. A few cases either harbor variant translo-
cations [t(v;22)] or cryptic rearrangement (1).
However, additional chromosome abnormalities (ACAs) 
are a recurring event associated with clonal evolution. An 
extra Ph, +8, i(17q) and +19 have been described as the most 
common secondary changes (known as the major route), 
whereas others infrequent changes have been labeled as the 
minor route. The major route of ACAs is usually detected 
during disease progression into the accelerated phase or blast 
crisis (2). At diagnosis, this has been documented with low 
frequency (<5% of cases) (3). These aberrations have been 
reported as an independent prognostic factor with a negative 
impact on the cytogenetic and molecular response (4,5). The 
t(1;11)(q21;q23) translocation has been described at diagnosis 
in certain cases of pediatric acute myeloid leukemia or myelo-
monocytic leukemia, with a poor prognosis, but the subgroup 
with this rearrangement suggests an uncertain impact in the 
outcome of acute leukemia (6).
The present study reports a rare case of CML with a 
cryptic Ph chromosome and a t(1;11)(q21;q23) translocation 
at diagnosis, with unfavourable responses, even though the 
patient received appropriate treatments. Furthermore, a T315I 
mutation was later detected in the patient.
Case report
In June 2000, a 47-year-old female with a CML diagnosis 
was referred to the Hematology Research Institute ‘Mariano 
R. Castex’, National Academy of Medicine (Buenos Aires, 
Argentina) for further studies and treatment. The clinical 
records of the patient indicated the onset of the disease in 
1998, when the patient was 45 years old, with a cytogenetic 
study showing the translocation t(1;11)(q21;q23). The patient 
was treated with hydroxyurea (1 g/day).
In the first consultation at the current institute, the patient 
presented with fatigue, weakness, fever and splenomegaly 
(4 cm below the costal margin). Laboratory results were as 
follows: Hematocrit, 36% (normal range, 36-46%); haemo-
globin, 11 g/dl (normal range, 11.5-15.5 g/dl); white blood cells 
(WBC), 11.2x109/l (normal range, 4.5-10.5x109/l); platelets, 
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5.90x1011/l (normal range, 1.5-4.0x1011/l); reticulocytes, 1.2% 
(normal range, 0.9-5.5%); LDH, 205 U/l (normal range, 
100-200 U/l). Bone marrow biopsy revealed hyper-cellularity 
with granulocytic hyperplasia, which was consistent with a 
diagnosis of chronic phase CML.
The cytogenetic analysis by G banding (7) confirmed t(1;11)
(q21;q23), add(9)(q34) and a cryptic Ph chromosome (Fig. 1) 
[detected by fluorescence in situ hybridization (FISH) simple 
fusion using DAKO DNA Probes; Dako, Glostrup, Denmark]. 
The molecular analysis by reverse transcription-polymerase 
chain reaction (RT-PCR) (8) showed the chimeric breakpoint 
cluster region-Abelson murine leukemia viral oncogene 
homolog 1 (BCR‑ABL1) mRNA transcripts. To determine 
whether the chromosome marker t(1;11) was of constitutional 
origin, a phytohemaglutinin-stimulated peripheral blood 
culture was performed. A normal karyotype was detected, 
which excluded the constitutional origin and indicated 
clonality.
The patient started treatment with hydroxyurea (1 and 2 g 
on alternate days) and interferon α (4.5 MU/day) until 2002 
when interferon therapy was discontinued due to intolerance. 
With these treatments, the patient only achieved a complete 
haematological response. On September 2005, the patient 
started treatment with imatinib (400 mg/day) and mild adverse 
events were observed, including facial and lower limb edema, 
and a minor cutaneous rash.
The patient achieved a hematological response without 
a cytogenetic and molecular response after 8 months of 
therapy. In October 2006, a laboratory analysis showed the 
following: Hematocrit, 41.2%; hemoglobin, 12.5%; WBC, 
9.3x109/l; and platelets, 9.50x1011/l. The dose of imatinib was 
increased to 600 mg/day and then to 800 mg/day in 2007 
for better control of the thrombocytosis and to enhance the 
responses.
In May 2009, due to increased platelets counts of 1.39x1012/l 
and the absence of a major cytogenetic response, the treat-
ment was switched to 800 mg/day nilotinib. After 15 months 
of treatment, the patient achieved a complete hematological 
response, and FISH studies showed 69% of cells positive for 
BCR‑ABL1 (BCR‑ABL1 dual fusion-dual color, LIVe Probes; 
Lexel, Buenos Aires, Argentina) (Fig. 2A). Quantification by 
RT-quantitative (q)PCR (MolecularMD® One-Step qRT-PCR 
BCR-ABL kit), according to the International Scale, gave a 
result of 8.5%, representing a minimal molecular response.
In October 2010, following adequate treatment adherence, 
the patient maintained the complete hematological response 
and exhibited reduced levels of BCR‑ABL1 transcripts at 0.84% 
(minor molecular response). Treatment was sustained between 
2011 and 2013 with good tolerance, but without significant 
changes in cytogenetic and molecular responses (values range 
from 20.0-24.5% of Ph-positive cells by FISH analysis and 
3.23-5.00% of BCR‑ABL1 transcripts by RT-qPCR). At the 
end of 2013, pegylated interferon (80 µcg/15 days) was added 
to treatment with nilotinib in order to improve responses, but 
not better outcome was observed.
In 2014, the patient's condition worsened, with levels 
of BCR‑ABL1 transcript reaching of 12.3% and with 71% 
Ph-positive cells, as determined by FISH. The treatment 
was switched to dasatinib (50 mg/day). In June 2015, cytoge-
netic control follow-up showed the karyotype 46,XX,t(1;11)
(q21;q23), add(9)(q34) in all metaphases and RT-qPCR 
detected 100% of BCR‑ABL1 transcripts.
An obstructed carotid artery was diagnosed during the 
control follow-up. After 2 months, the screening for mutations 
in the ABL1 gene by direct sequencing (9) detected the T315I 
mutation. Treatment with tyrosine kinase inhibitor (TKI) was 
suspended. A carotid artery angioplasty was performed and 
omacetaxine was prescribed at an induction dose (1.25 mg/m2) 
by subcutaneous injection twice daily for 14 consecutive days. 
Grade 3 anemia and grade 2 thrombocytopenia were observed, 
and the patient received blood red cells transfusions. With a 
delay of 6 days, a second cycle was administered at the same 
dosage but for 9 days only. To date, the patient has progressed 
to blast crisis and is receiving transfusions and supportive care 
for febrile neutropenia, and chemotherapy is under evaluation. 
Bone marrow transplantation was not an option, as the only 
sibling available as a donor for stem cell transplant was unfit 
due to histocompatibility and limiting comorbidities.
In order to assess if MLL [also known as lysine methyl-
transferase 2A (KMT2A)] was affected by the t(1;11)(q21;q23) 
translocation, FISH was performed using a dual color-split 
signal probes (Cytocell Aquarius probes; Cytocell, Cambridge, 
UK). The pattern of signal observed was not consistent with 
alterations in this gene (data not shown), indicating that the 
MLL gene was not split by the t(1;11) translocation.
Finally, to determine if the cryptic Ph chromosome was 
the result of a variant translocation, involving chromosomes 
1, 9, 11 and 22, a whole chromosome painting (WCP) of 
chromosomes 1 and 11 was performed (WCP LIVe Probes; 
Lexel), as previously described (10). The results indicated that 
the t(1;11)(q21;q23) translocation and cryptic Ph chromosome 
had an independent origin (Fig. 2B). The FISH analysis could 
not determine the nature of the extra material in add(9q).
The experiments performed in this study were approved 
by the Ethics Committee of the Institutes of the National 
Academy of Medicine (Buenos Aires, Argentina) and the 
patient provided written informed consent for the publication 
of the study.
Discussion
In CML patients, ACAs in Ph-positive cells affect the progres-
sion and response to treatment according to the chromosome 
aberration and time of appearance. The European Leukemi-
aNet guidelines suggest that the presence of ACAs at diagnosis 
may represent a ‘warning’ feature, requiring careful moni-
toring (11). ACAs at diagnosis have been observed in ~5% of 
cases and are associated with clonal evolution, the mechanism 
of resistance and an adverse prognosis under treatment with 
imatinib (3). A previous study showed that the presence of 
ACAs in the early chronic phase was one of the indepen-
dent adverse predictors for progression within a year (12). 
Fabarius et al reported that only the major route ACAs [+8, 
+Ph and i(17q)] at diagnosis are associated with a negative 
impact on progression-free and overall survival times (13). 
However, the impact of ACAs at diagnosis and their prognostic 
significance are issues that remain under discussion.
The present study reports the case of a CML patient who 
presented with a reciprocal translocation between chromo-
somes 1 and 11 [t(1;11)(q21;q23)], add(9q34) and a cryptic Ph 
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chromosome at diagnosis. Genetic alterations in 11q23 are 
frequent in hematological malignancies, particularly in acute 
leukemia (6). These alterations affect the MLL gene in ~85% 
of cases and are associated with an adverse prognosis (14). In 
CML, alterations involving 11q23 and affecting MLL are rare, 
and have been reported only sporadically (15-19). However, 
this translocation could affect other genes such as CBL, gener-
ating a new chimeric gene that could deregulate the cell cycle 
and affect the treatment response (20,21).
Through use of BCR‑ABL1 dual fusion-dual color FISH 
probes (LIVe Probes; Lexel), as previously described (22), 
the present study found the absence of a second fusion signal 
on der (9), keeping only the residual signal of the ABL1 gene, 
which is indicative of the deletion of the BCR sequence on 
der (9) (Fig. 2A). This deletion was confirmed by molecular 
analysis of the reciprocal transcript ABL1‑BCR (data not 
shown). Deletions on der (9) have been reported in several 
studies in association with a bad response prior to the TKI 
era (6,11,23).
One of the most important mechanisms of resistance is via 
acquired mutations in the tyrosine kinase domain of ABL1. 
The T315I mutation was detected in the present patient during 
the last year of follow-up. This mutation is associated with the 
resistance to the majority of TKIs (24,25).
Figure 1. Metaphase showing translocation t(1;11)(q21;q23) and the add(9)(q34). The arrows indicate the chromosomes involved.
Figure 2. (A) FISH of the breakpoint cluster region-ABL 1 gene (dual fusion-dual color). The white arrow indicates the Ph chromosome and the yellow arrow 
shows the chromosome der(9) with the residual ABL signal. (B) Painting FISH for chromosomes 1 and 11. The white arrow indicates the chromosome der(1) 
and the yellow arrow shows der(11). The absence of red or green signals on other chromosomes discounts a variant Ph, indicating an independent origin for the 
t(1;11)(q21;q23). Ph, Philadelphia; FISH, fluorescence in situ hybridization; ABL, Abelson murine leukemia viral oncogene homolog 1.
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Although a long overall survival time (>15 years) was 
experienced in the present study, the CML patient has since 
progressed to a blast crisis. At present, the patient is receiving 
transfusions and supportive care for severe febrile neutropenia. 
Throughout the course of the disease, only a hematological 
response was achieved, with an occasional partial cytoge-
netic response and a lack of a molecular response, despite an 
increased dose of imatinib (from 400 to 600 to 800 mg/day) 
and a switch to second-generation TKIs (nilotinib and dasat-
inib). In the early stages, the t(1;11)(q21;q23) may have played a 
negative role in the outcome. Whether this atypical transloca-
tion may trigger the emergence of the T315I mutation CML is 
a matter for further investigation.
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